NDA 205832 · Boehringer Ingelheim
Ofev
Nintedanib Esylate · Oral
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Oct 15, 2014
Approved uses
3
Original approval plus efficacy supplements
Registered trials
170
30 Phase 3, 10 recruiting
FAERS reports
32,515
22,042 serious, 6,449 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 20, 2025.
OFEV is a kinase inhibitor indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF) ( 1.1 ) Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype ( 1.2 ) Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) ( 1.3 ) 1.1 Idiopathic Pulmonary Fibrosis OFEV is indicated for the treatment of adults with idiopathic pulmonary fibrosis (IPF). 1.2 Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype OFEV is indicated for the treatment of adults with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype [see Clinical Studies (14.2) ] . 1.3 Systemic Sclerosis-Associated Interstitial Lung Disease OFEV is indicated to slow the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Mechanism: Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, colony stimulating factor 1 receptor (CSF1R), and Fms-like tyrosine kinase-3 (FLT-3). These kinases except for FLT-3 have been implicated in pathogenesis of interstitial lung diseases (ILD). Nintedanib binds competitively to the adenosine triphosphate (ATP) binding...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 9, 2020 Supplement 13 · Efficacy · priority review Breakthrough therapyLabelLetterReview
- Sep 6, 2019 Supplement 12 · Efficacy · priority review OrphanLetterLabelReview
- Oct 15, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
2 products under this application
- OFEV · NINTEDANIB ESYLATE EQ 150MG BASE · CAPSULE, ORAL · Prescription · TE AB
- OFEV · NINTEDANIB ESYLATE EQ 100MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Nintedanib Esylate" as an intervention, any sponsor and status, largest first.
- LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian CancerPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01015118 · 1,366 participants · Start Nov 17, 2009 · Primary completion Apr 1, 2013
Drug: Placebo; Paclitaxel and 4 more · For: Ovarian Neoplasms; Peritoneal Neoplasms
Sites: Tucson, Arizona; Long Beach, California; Santa Rosa, California · 281 sites in all
- LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung CancerPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00805194 · 1,314 participants · Start Dec 3, 2008 · Primary completion Nov 2, 2010
Drug: placebo plus docetaxel; BIBF 1120 plus docetaxel · For: Carcinoma, Non-Small-Cell Lung
Sites: Graz, Austria; Kufstein, Austria; Linz, Austria · 210 sites in all
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CarePivotal-lookingTerminated
Lakefront Biotherapeutics NVIndustry
NCT03733444 · 781 participants · Start Nov 5, 2018 · Primary completion Mar 30, 2021
Drug: GLPG1690; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 132 sites in all
- Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02149108 · 768 participants · Start Sep 25, 2014 · Primary completion May 13, 2016
Drug: Nintedanib (BIBF 1120); Placebo and 2 more · For: Colorectal Neoplasms
Sites: Los Angeles, California; New Haven, Connecticut; Plainville, Connecticut · 129 sites in all
- Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01619085 · 752 participants · Start Jun 6, 2012 · Primary completion Jul 5, 2017
Drug: Nintedanib · For: Idiopathic Pulmonary Fibrosis
Sites: Jasper, Alabama; Phoenix, Arizona; Los Angeles, California · 173 sites in all
- Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLCPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00806819 · 718 participants · Start Dec 2008 · Primary completion Jun 2011
Drug: Nintedanib (BIBF1120); Pemetrexed and 14 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Downy, California; Fountain Valley, California; Fullerton, California · 163 sites in all
- Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02999178 · 663 participants · Start Jan 17, 2017 · Primary completion Apr 23, 2019
Drug: Nintedanib; Placebo · For: Lung Diseases, Interstitial
Sites: Birmingham, Alabama; Los Angeles, California; Sacramento, California · 153 sites in all
- A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung FibrosisPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02597933 · 580 participants · Start Nov 12, 2015 · Primary completion Oct 31, 2018
Drug: Nintedanib; Placebo · For: Scleroderma, Systemic
Sites: Birmingham, Alabama; Los Angeles, California; Sacramento, California · 195 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea10,539
- nausea4,818
- dyspnoea4,179
- cough3,397
- death3,386
- decreased appetite3,188
- weight decreased3,173
- fatigue3,033
- vomiting2,828
- idiopathic pulmonary fibrosis2,209
- headache2,071
- constipation2,053
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 36 |
| 2015 | 960 |
| 2016 | 1,298 |
| 2017 | 1,463 |
| 2018 | 1,924 |
| 2019 | 2,057 |
| 2020 | 2,461 |
| 2021 | 3,012 |
| 2022 | 3,745 |
| 2023 | 3,790 |
| 2024 | 4,276 |
| 2025 | 3,898 |
| 2026 | 3,591 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ofev (Nintedanib Esylate)
2024 spending
$2.09B
Beneficiaries
23,929
161,717 claims
Per beneficiary
$87,191
$216.45 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,157,563,828 |
| 2021 | $1,495,198,249 |
| 2022 | $1,762,963,783 |
| 2023 | $1,837,061,150 |
| 2024 | $2,086,398,979 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review.
Al Oweidat KS, Abdulelah AA, Toubasi AA, et al. · Can Respir J 2025 · Systematic Review
- A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Rinciog C, Watkins M, Chang S, et al. · Pharmacoeconomics 2017 · Comparative Study, Network Meta-Analysis
- Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer.
Dallinger C, Trommeshauser D, Marzin K, et al. · J Clin Pharmacol 2016 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.